Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure

Paul G. Richardson(Harvard University), Robert J. Soiffer(Dana-Farber Cancer Institute), Marcie Riches(Medical College of Wisconsin), Leslie Lehmann(Harvard University), Joseph M. Massaro(Boston University), Joel A. Brochstein(Cohen Children's Medical Center), Alfred P. Gillio(University Medical Center), Ralph B. D’Agostino(Wake Forest University), Eneida R. Nemecek(Oregon Health & Science University), Sally Arai(Stanford Medicine), Richard E. Champlin(The University of Texas MD Anderson Cancer Center), Joseph H. Antin(Dana-Farber Cancer Institute), Eva C. Guinan(Dana-Farber Cancer Institute), Shin Mineishi(University of Alabama at Birmingham), Sergio Giralt(Memorial Sloan Kettering Cancer Center), Tulio E. Rodriguez(Loyola University Medical Center), Massimo Iacobelli(Figli Adottivi e Genitori Naturali), Gideon Steinbach(University of Washington), Angela R. Smith(University of Minnesota Children's Hospital), Stephan A. Grupp(Children's Hospital of Philadelphia), Nancy A. Kernan(Memorial Sloan Kettering Cancer Center), Maja Miloslavsky(Janssen (United States)), Bijan Nejadnik(Janssen (United States)), Alison L. Hannah(CytomX Therapeutics (United States)), John Doyle(Analysis Group (United States)), Paul L. Martin(Duke University), Reggie Duerst(Lurie Children's Hospital), Diane Warren(Dana-Farber Cancer Institute), Robin Hume(Jazz Pharmaceuticals (United States)), Rajinder Bajwa(Nationwide Children's Hospital), Amrita Krishnan(City of Hope), Amanda Termuhlen
Blood
January 29, 2016
Cited by 333


Related Papers